Curis (CRIS) EBITDA Margin (2010 - 2025)
Curis' (CRIS) quarterly EBITDA Margin came in at 1723.99% in Q4 2025, up 199287.0% on a YoY basis from N/an in Q4 2024, and up 890.78% quarter-over-quarter from 218.01% in Q3 2025.
Powered by 
Analysis
Curis (CRIS) EBITDA Margin (2010 - 2025) Analysis & Trends
Curis (CRIS) has reported EBITDA Margin for 16 consecutive years, with 1723.99% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin rose 199287.0% year-over-year to 1723.99%; the trailing twelve-month figure through Jun 2026 stood at 203.15% (up 12976.0% YoY), and the FY2025 full-year result was 60.5%, up 34784.0% from the prior year.
- EBITDA Margin advanced to 1723.99% in Q4 2025 per CRIS's latest filing, from 218.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1723.99% in Q4 2025 and bottomed at 735.68% in Q1 2022.
- Historically, EBITDA Margin has averaged 332.6% across 5 years, with a median of 431.67% in 2025.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin tumbled 33367 bps in 2022, then jumped 199287 bps in 2025.
- Over 5 years, EBITDA Margin stood at 400.86% in 2021, then rose by 12 bps to 354.0% in 2022, then decreased by 28 bps to 452.49% in 2023, then soared by 41 bps to 268.88% in 2024, then jumped by 741 bps to 1723.99% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1723.99%, 218.01%, and 300.15% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | Curis | 2.63 Mn | -2.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1,723.99% |
| Sep 30, 2025 | -218.01% |
| Jun 30, 2025 | -300.15% |
| Mar 31, 2025 | -426.76% |
| Dec 31, 2024 | -268.88% |
| Sep 30, 2024 | -360.53% |
| Jun 30, 2024 | -491.44% |
| Mar 31, 2024 | -597.75% |
| Dec 31, 2023 | -452.49% |
| Sep 30, 2023 | -436.57% |
| Jun 30, 2023 | -552.48% |
| Mar 31, 2023 | -506.18% |
| Dec 31, 2022 | -354.00% |
| Sep 30, 2022 | -446.23% |
| Jun 30, 2022 | -629.38% |
| Mar 31, 2022 | -735.68% |
| Dec 31, 2021 | -400.86% |
| Sep 30, 2021 | -330.64% |
| Jun 30, 2021 | -465.88% |
| Mar 31, 2021 | -402.01% |